Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?
Selective inhibition by riluzole of voltage-dependent sodium channels and catecholamine secretion in adrenal chromaffin cells.
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.
Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Multiple Sclerosis: Does Nogo Play a Role?
LSN MS guidelines for the management of multiple sclerosis.
Assessing spinal cord function in multiple sclerosis with functional neuroimaging: insights and limitations.
Does jcv antibody positivity encourage cessation of natalizumab therapy in multiple sclerosis?
The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.
Biointegrator announced that it has successfully launched Neskler® - a first generic of Gilenya® in Russia and EuroAsian Economic Union
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
Chromatin Landscape Defined by Repressive Histone Methylation during Oligodendrocyte Differentiation.
Spinocerebellar Ataxias Type 8, 12, and 17 and Dentatorubro-Pallidoluysian Atrophy in Czech Ataxic Patients.
Correction: Combined Acquisition Technique (CAT) for Neuroimaging of Multiple Sclerosis at Low Specific Absorption Rates (SAR).
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease.
[Optic Neuritis.]
A passive exoskeleton can push your life up: application on multiple sclerosis patients.
Visual resting-state network in relapsing-remitting MS with and without previous optic neuritis.
Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
Autophagy in immunity: Implications in etiology of autoimmune/autoinflammatory diseases.
Recurrent Varicella following Steroids and Fingolimod in a Multiple Sclerosis Patient.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis.
Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-Beta.
Pages
« first
‹ previous
…
259
260
261
262
263
264
265
266
267
…
next ›
last »